MYELOID MALIGNANCY

This study tests a new drug called lisaftoclax, given alone or with other medicines, for people whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The main goals are to check safety and find the best dose. About 682 adults will take part. T…

This study tests a new combination of three drugs (mitoxantrone, cytarabine, and venetoclax) for adults whose acute myeloid leukemia has come back or not responded to earlier treatment. The goal is to see if this combination can help more patients achieve remission. About 72 part…

This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a stem cell transplant can prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 20 participants will receive the treatment f…

This early-stage study tests whether adding two drugs, decitabine and venetoclax, to a standard stem cell transplant can make the procedure safer for people with aggressive blood cancers like leukemia. About 20 adults aged 18-75 with a matched donor will receive the experimental …

This study tests whether a low dose of the drug azacitidine can help maintain or increase the level of donor cells in patients with certain blood cancers (MDS, AML, CMML, MPN) after a stem cell transplant. The goal is to reduce the chance of the cancer coming back. About 43 adult…

This study tests whether watching digital stories from other patients helps people with myeloid cancers (like AML or MDS) decide about a stem cell transplant. About 120 adults will either watch these stories or receive usual care. The goal is to see if this approach is practical …

This study is testing a new gene panel called MyeloGen to see if it can find inherited genetic risks in 200 adults with myeloid blood cancers. Participants will give a skin sample, and researchers will check if results can be returned within 10 weeks. The goal is to learn how wel…

This study tests a telehealth program to help older patients (60+) with blood cancers like leukemia and MDS communicate better with their doctors and complete advance care plans. About 207 patients and their caregivers will be randomly assigned to the program or usual care. The g…

This study uses advanced genetic testing (next generation sequencing) to look for early warning signs of pre-myeloid cancers and bone marrow failure in 2000 people. Participants have certain blood abnormalities or genetic markers that may increase their risk. The goal is to bette…